GB-115

Description

GB-115

Ranquilon, N-phenylacetyl-L-prolylglycine ethyl ester

GB-115 is an experimental dipeptide with anxiolytic properties, developed from research on cholecystokinin-related peptides. It is being investigated for its potential to reduce stress, regulate anxiety, support emotional resilience, and maintain cognitive equilibrium. Unlike conventional sedative anxiolytics, GB-115 has drawn interest in nootropic and neuropeptide circles due to its ability to promote calmness without causing pronounced drowsiness or impairing mental clarity. Scientific interest centers on its interaction with CCK receptor systems and its possible role in modulating stress response mechanisms and neurotransmitter activity.

• Status: Phase 3 trials completed for anxiety and adjustment disorders; not approved for use outside Russia. Evidence based on human clinical trials.
• Standard dosage: 6 mg per day, divided into two or three doses (e.g., morning, afternoon, and evening), with each dose being 2 mg. Available as oral or sublingual tablets.
• Investigated uses: Management of anxiety, symptoms of ADHD, improved focus, and enhanced cognitive performance.